论文部分内容阅读
目的检测p53蛋白在非小细胞肺癌患者中的表达水平,并探讨其表达与临床特征的相关性及同步放化疗疗效的关系。方法采用免疫组化方法,检测100例非小细胞肺癌组织中p53表达水平,结合显微图像分析仪测定p53免疫组化强度,以阳性单位为定量分析单位。分析p53表达水平与患者临床病理特征及同步放化疗疗效的关系。结果 p53蛋白在非小细胞肺癌中阳性表达率为48%;p53表达与淋巴结转移、远端转移和TNM分期均无显著相关性;非小细胞肺癌p53蛋白表达者放化疗效果显著低于p53蛋白表达阴性患者,且p53蛋白表达与患者生存期呈负相关。结论 p53表达与否影响非小细胞肺癌患者化疗效果,与生存期直接相关,临床治疗时可考虑将其作为治疗靶点。
Objective To detect the expression of p53 protein in patients with non-small cell lung cancer (NSCLC) and to explore the relationship between its expression and clinical features and the efficacy of concurrent chemoradiotherapy. Methods Immunohistochemistry was used to detect the expression of p53 in 100 non-small cell lung cancer tissues. The intensity of p53 immunohistochemistry was determined by microscopic image analyzer. The positive units were quantitatively analyzed. To analyze the relationship between the expression of p53 and clinicopathological features and the efficacy of concurrent chemoradiotherapy. Results The positive expression rate of p53 protein in non-small cell lung cancer was 48%. There was no significant correlation between p53 expression and lymph node metastasis, distant metastasis and TNM staging. The expression of p53 protein in non-small cell lung cancer was significantly lower than that of p53 protein Negative patients, and p53 protein expression and patient survival was negatively correlated. Conclusion The expression of p53 may affect the chemotherapeutic effect in patients with non-small cell lung cancer and is directly related to the survival time. It may be considered as a therapeutic target in clinical treatment.